Cost-effectiveness analysis of atorvastatin versus simvastatin as lipid-lowering treatment for primary care patients with hypercholesterolaemia

Atencion Primaria

Volumn 27, Issue 1, 2001, Pages 18-24

  Tarraga Lopez P J ^a   Celada Rodriguez A ^a   Cerdan Oliver M ^b   Solero Albero, J ^c   Ocana Lopez J M ^c   De Miguel Clave J ^d  

^a Centro de Salud de Casas Ibanez   (Spain)

^b Centro Salud de Casas de Juan Núñez   (Spain)

^c Centro de Salud de Alcaraz   (Spain)

^d Centro de Salud de Belmonte   (Spain)

Author keywords

Atorvastatin; Cost effectiveness; Lipid lowering therapy; Primary care; Simvastatin

Indexed keywords

ATORVASTATIN; SIMVASTATIN;

ADULT; AGED; ARTICLE; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; DRUG EFFICACY; FEMALE; HUMAN; HYPERCHOLESTEROLEMIA; LIPOPROTEIN BLOOD LEVEL; MAJOR CLINICAL STUDY; MALE; RANDOMIZED CONTROLLED TRIAL; TRIACYLGLYCEROL BLOOD LEVEL;

EID: 0035125299     PISSN: 02126567     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0212-6567(01)78767-7     Document Type: Article

References (41)

1. Trends in cardiovascular disease mortality in industrialized countries since 1950
2. Comparación de las tendencias de mortalidad por enfermedades isquémicas del corazón y otras cardiovasculares entre España y otros países desarrollados 1970-1980
3. Mortalidad por enfermedad isquémica del corazón
4. Recent coronary heart disease mortality trends in Spain
5. Perspectiva epidemiológica del riesgo en España
6. Mortalidad cardiovascular en España y sus comunidades autónomas
7. Factores de riesgo en la enfermedad coronaria. Experiencia del seguimiento durante tres décadas del estudio Framingham
8. Coronary heart disease in seven countries
9. Sociedad española de medicina interna y liga para lucha contra la hipertensión arterial. Recomendaciones para la prevención primaria de la enfermedad cardiovascular
10. Second report of the expert panel on detection, evaluation and treatment of high blood cholesterol in adults (adult treatment panel II)
11. Randomised trial of cholesterol lowering in 4444 patients with coronary heart disease: The scandinavian simvastatin survival study (4S)
12. The effect of pravastatin on coronary events after cardial infartions in patients with average cholesterol levels
13. Statin trials on goals of cholesterol lowering therapy
14. Factores que condicionan la efectividad y las indicaciones de las estatinas en prevención cardiovascular
15. Simvastatin cost-effective in secondary prevention
16. Cost effectiveness of LDL-c reduction in medicare magnaged care cHDL patients; implication from the scancinavian simvastatin survival study (HS)
17. Cost implications of lipid lowering treatments
18. Task Force G. Cost effectiveness of assesment and management of risk factors
19. Relevancia de la mortalidad por enfermedades circulatorias en España
20. Cost-effectiveness of pravastatin in secondary prevention of coronary artery disease
21. Cost-effectiveness of simvastatin treatment to lower cholesterol levels in patients with coronary heart disease
22. Utilización de recursos en el tratamiento de las dislipemias
23. Coste del tratamiento de la dislipemia con la utilización de las directrices del National Cholesterol Education Program (NCEP)
24. Estudio epidemiológico de los factores de riesgo cardiovascular en la población española de 35 a 64 años
25. Hunninghake D por los investigadores del estudio CURVES. Estudio comparativo de la relación dosis-eficacia de atorvastatina frente a simvastatina, pravastatina, lovastatina y fluvastatina en pacientes con hipercolesterolemia (estudio CURVES)
26. Farmacoeconomía: El cálculo de la eficiencia
27. Evaluación económica aplicada al campo de los medicamentos. Características y metodología
28. Clinical benefits and cost-effectiveness of lowering serum cholesterol levels: The case of simvastatin and cholestyramine in the Netherlands
29. Cost effectiveness of treatment to National Cholesterol Education Panel (NCEP) targets with HMG-CoA reductase inhibitors
30. Alcanzar los objetivos del «National Cholesterol Education Program» (NCEP) sobre el colesterol en la práctica clínica: Comparación de lovastatina y fluvastatina en la prevención primaria
31. Primary prevention of acute coronary events with lovastatin in men and woman with average cholesterol levels: Results of AFCAPS/TexCAPS
32. Pharmacoeconomic assessment of HMG-CoA reductase inhibitor therapy: An analysis based on the CURVES study
33. A population-based treat-to-target pharmacoeconomic analysis of HMG-CoA reductase inhibitors in hypercholesterolemia
34. Critical evaluation of a cost-effectiveness analysis of four HMG-CoA reductase inhibitors
35. Which statin is most efficient for the treatment of hypercholesterolemia? A cost-effectiveness analysis
36. Cost-effectiveness of statins
37. A comparative economic analysis of simvastatin versus atorvastatin: Results of the surrogate marker cost-efficacy (SmaC) study